Manitex Capital Inc. (V:MNX)
Business Focus: Pharmaceuticals (NEC)
Feb 28, 2024 05:43 pm ET
Manitex Capital Reports Annual Financial Results
KIRKLAND, QC, Feb. 28, 2024 /CNW/ - Manitex Capital Inc. ("Manitex") reported today its financial results for the year ended October 31, 2023.
Oct 12, 2023 07:33 pm ET
Manitex Capital Announces Change of Auditor
KIRKLAND, QC, Oct. 12, 2023 /CNW/ - Manitex Capital Inc. (TSXV: MNX) ("Manitex" or the "Company") today announced that it has changed its auditor from MNP LLP (the "Former Auditor") to Audacie inc. (formerly, Guimond Lavallée Inc.) (the "Successor Auditor").
Aug 17, 2023 04:55 pm ET
Manitex Capital Announces Resignation of a Director and New Board Appointment
KIRKLAND, QC, Aug. 17, 2023 /CNW/ - Manitex Capital Inc. ("Manitex") announced today that Mr. Berge Etmekdjian has resigned as director of the Corporation and that the Board has appointed Mr. Michael Tinmouth as a new independent director. Mr. Tinmouth will also succeed Mr. Etmekdjian as Chair of the Audit Committee.
Feb 24, 2023 03:05 pm ET
Manitex Capital Reports Annual Financial Results
KIRKLAND, QC, Feb. 24, 2023 /CNW/ - Manitex Capital Inc. ("Manitex") reported today its financial results for the year ended October 31, 2022.
Sep 29, 2022 04:30 pm ET
Manitex Capital Reports Third Quarter Financial Results and Grants Options to its Officers
KIRKLAND, QC, Sept. 29, 2022 /CNW/ - Manitex Capital Inc. ("Manitex") reported today its financial results for the third quarter ended July 31, 2022.
Jun 29, 2022 07:00 pm ET
Manitex Capital Reports Second Quarter Financial Results and Grants Options to Certain Directors
KIRKLAND, QC, June 29, 2022 /CNW/ - Manitex Capital Inc. ("Manitex") reported today its financial results for the second quarter ended April 30, 2022.
Jun 30, 2020 10:00 pm ET
Manitex Capital Inc. Restates Previously Reported Q1 2020 Quarterly Financial Results and Grants Options to Certain Directors
KIRKLAND, QC, June 30, 2020 /CNW Telbec/ - Manitex Capital Inc. ("Manitex" or the "Company") announced today that it has filed a restatement of its previously reported financial results for January 31, 2020, together with a revised management discussion and analysis ("MD&A") for the quarter. The restatement was required due to an error in the calculation of the Deferred Tax Liability. The restated financial statements and revised MD&A are available on SEDAR at www.sedar.com.
Oct 10, 2019 02:17 am ET
Early Warning Report Filed Pursuant To National Instrument 62-103
This press release is being disseminated as required by National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues.
Aug 28, 2019 06:36 pm ET
Manitex Capital Inc. Completes Distribution of Dividend-In-Kind Consisting of Warrants of Valeo Pharma Inc.
KIRKLAND, QC, Aug. 28, 2019 /CNW Telbec/ - Manitex Capital Inc. ("Manitex") is pleased to announce that it has completed the distribution to its shareholders of its previously announced special dividend-in-kind (the "Dividend") of share purchase warrants of Valeo Pharma Inc., ("Valeo Warrants") held by Manitex.
Jul 30, 2019 05:26 pm ET
Manitex Capital Inc. declares a dividend-in-kind of warrants of Valeo Pharma Inc.
KIRKLAND, QC, July 30, 2019 /CNW Telbec/ - Manitex Capital Inc. (TSXV: MNX), ("Manitex"), is pleased to announce that its Board of Directors has declared a special dividend-in-kind (the "Dividend") of 1,256,127 share purchase warrants of Valeo Pharma Inc. (the "Valeo Warrants") held by Manitex. The Dividend shall have a deemed price per Valeo Warrant based on the closing price of the Valeo Warrants (VPH.WT) on the Canadian Securities Exchange (the "CSE") on the trading day prior to payment of the Dividend, expected to occur on or about August 28, 2019, to holders of record of common shares o
Apr 05, 2019 05:21 pm ET
Manitex Capital Inc. announces results of AGM
KIRKLAND, QC, April 5, 2019 /CNW Telbec/ - Manitex Capital Inc. ("Manitex" or the "Company") is pleased to announce the voting results from its Annual General and Special Meeting of shareholders (the "Meeting") held today in Kirkland, Quebec. The total number of shares represented by shareholders present in person and by proxy at the Meeting was 8,017,627 representing 63.83% of the Company's issued and outstanding shares.
Jan 15, 2019 08:02 am ET
Manitex Capital Inc.'s affiliate, Valeo Pharma Inc., announces approval of Onstryv® (safinamide) for Canada
KIRKLAND, QC, Jan. 15, 2019 /CNW Telbec/ - Manitex Capital Inc. (TSXV: MNX) announces that its affiliate, Valeo Pharma Inc., has received approval from Health Canada for a new Parkinson's Disease product ONSTRY® (safinamide) in Canada. Valeo Pharma plans to launch ONSTRYV® in Canada in the first half of 2019. Already launched in Europe and the U.S.A., ONSTRYV® will provide an important new option to the estimated 100,000 Canadians living with Parkinson's Disease.
Jan 11, 2019 04:23 pm ET
Manitex Capital Inc. declares a dividend-in-kind of shares of Valeo Pharma Inc.
KIRKLAND, QC, Jan. 11, 2019 /CNW Telbec/ - Manitex Capital Inc. ("Manitex") is pleased to announce that its board of directors has declared a special dividend-in-kind (the "Dividend") of 1,256,127 common shares of Valeo Pharma Inc., ("Valeo") held by Manitex. The Dividend has a deemed price of $0.40 per Valeo Share and is payable on, or about, February 1, 2019 to holders of record of common shares of Manitex ("Manitex Shares") at the close of business on January 22, 2019 (the "Record Date").
Nov 21, 2018 04:39 pm ET
Manitex Capital Inc. announces director resignation
KIRKLAND, QC, Nov. 21, 2018 /CNW Telbec/ - Manitex Capital Inc. ("Manitex" or the "Corporation") announces that Mr. David Ben-David has resigned from its Board of Directors effective immediately. Manitex would like to thank Mr. Ben-David for his contribution to the Corporation since joining the Board in 1998 and wishes him well in his other business endeavours.
Oct 01, 2018 07:57 am ET
Manitex Capital Inc. Announces That Its Affiliate Valeo Pharma Inc. Has Filed a Non-Offering Preliminary Prospectus
KIRKLAND, QC, Oct. 1, 2018 /CNW Telbec/ - Manitex Capital Inc. ("Manitex") (TSXV: MNX) is pleased to announce that its affiliate, Valeo Pharma Inc. ("Valeo Pharma"), has filed a non-offering preliminary prospectus with the securities regulatory authorities of all provinces and territories in Canada.
Oct 12, 2017 07:29 pm ET
Manitex Capital Inc. completes distribution of dividend-in-kind of shares of Auxico Resources Canada Inc.
KIRKLAND, QC, Oct. 12, 2017 /CNW Telbec/ - Manitex Capital Inc. ("Manitex") is pleased to announce that it has completed the distribution to its shareholders of its previously announced special dividend-in-kind (the "Dividend") of common shares of Auxico Resources Canada Inc., ("Auxico Shares") held by Manitex.
Sep 11, 2017 06:37 pm ET
Manitex Capital Inc. declares a dividend-in-kind of shares of Auxico Resources Canada Inc.
KIRKLAND, QC, Sept. 11, 2017 CNW Telbec/ - Manitex Capital Inc. ("Manitex") is pleased to announce that its board of directors has declared a special dividend-in-kind (the "Dividend") of 1,256,127 common shares of Auxico Resources Canada Inc., ("Auxico Shares") held by Manitex. The Dividend has a deemed price of $0.25 per Auxico Share and is payable on, or about, October 3, 2017 to holders of record of common shares of Manitex ("Manitex Shares") at the close of business on September 19, 2017 (the "Record Date").
Apr 11, 2017 08:55 am ET
Manitex Capital Inc.'s affiliate, Valeo Pharma Inc., announces partnership for a Parkinson's disease treatment
KIRKLAND, QC, April 11, 2017 /CNW Telbec/ - Manitex Capital Inc. (TSXV: MNX) announces that its affiliate, Valeo Pharma Inc,. has entered into a partnership with Zambon S.p.A. for the exclusive Canadian rights to commercialize the new Parkinson's disease product Xadago® (safinamide) in Canada. World Parkinson's Day is observed every year on April 11 to commemorate the birthday of Dr. James Parkinson, the English physician who first described the symptoms of the disease. Today marks 200 years since the publication of his seminal 1817 work "An Essay on the Shaking Palsy".
Mar 30, 2017 05:05 pm ET
Manitex Capital Inc. restates previously reported 2016 quarterly financial results
KIRKLAND, QC, March 30, 2017 /CNW Telbec/ - Manitex Capital Inc. ("Manitex" or the "Corporation") announced today that it has filed a restatement of its previously reported financial results for the 2016 quarters, together with a revised management discussion and analysis ("MD&A") for each respective quarter. The restated financial statements and revised MD&A are available on SEDAR at www.sedar.com.
Mar 02, 2017 05:45 pm ET
Manitex Capital Inc. adopts a new 20% fixed incentive stock option plan
KIRKLAND, QC, March 2, 2017 /CNW Telbec/ - Manitex Capital Inc. ("Manitex" or the "Corporation") announces that the Board of Directors has adopted a new 20% fixed incentive stock option plan (the "New Plan") to convert and replace the previous stock option plan and enhance the Corporation's ability to compensate employees, officers and directors by means other than cash incentives.
Jan 23, 2017 02:22 pm ET
Manitex Capital Inc. invests in Auxico Resources Canada Inc. and provides advisory services on going-public transaction
KIRKLAND, QC, Jan. 23, 2017 /CNW Telbec/ – Manitex Capital Inc. ("Manitex") is pleased to announce that it has subscribed for and purchased 2,000,000 common shares (the "Shares") of Auxico Resources Canada Inc. ("Auxico") at a subscription price of $0.25 per Share, for an aggregate principal amount of $500,000 (the "Investment").
Sep 22, 2016 05:01 pm ET
Manitex Capital Inc. acquires convertible debentures of Cold Water Fisheries Inc. and provides advisory services on going-public transaction
KIRKLAND, QC, Sept. 22, 2016 /CNW Telbec/ - Manitex Capital Inc. ("Manitex") is pleased to announce that it has subscribed for and purchased unsecured convertible debentures (the "Debentures") of Cold Water Fisheries Inc. ("CWF") for an aggregate principal amount of $700,000 (the "Principal Amount").
Jun 06, 2016 09:00 am ET
Manitex Capital Inc. announces completion of dividend-in-kind of shares of Ortho Regenerative Technologies Inc.
KIRKLAND, QC, June 6, 2016 /CNW Telbec/ - Manitex Capital Inc. ("Manitex") is pleased to announce that it has completed on June 3, 2106 its previously announced special dividend-in-kind (the "Dividend") of 1,121,142 Class "A" common shares of Ortho Regenerative Technologies Inc., ("Ortho Shares") held by Manitex. The Dividend has a deemed price of $0.50 per Ortho Share and was distributed to holders of record of common shares of Manitex ("Manitex Shares") at the close of business on May 20, 2016 (the "Record Date"). No Ortho Shares were delivered to Manitex shareholders residing outside of C
May 10, 2016 05:51 pm ET
Manitex Capital Inc. declares a dividend-in-kind of shares of Ortho Regenerative Technologies Inc.
KIRKLAND, QC, May 10, 2016 /CNW Telbec/ - Manitex Capital Inc. ("Manitex") is pleased to announce that its board of directors has declared a special dividend-in-kind (the "Dividend") of 1,256,127 Class "A" common shares of Ortho Regenerative Technologies Inc., ("Ortho Shares") held by Manitex. The Dividend has a deemed price of $0.50 per Ortho Share and is payable on, or about, June 3, 2016 to holders of record of common shares of Manitex ("Manitex Shares") at the close of business on May 20, 2016 (the "Record Date").
Apr 29, 2016 05:01 pm ET
Mar 24, 2016 07:47 pm ET
Manitex Capital Inc. announces that its affiliate, Ortho Regenerative Technologies Inc., has filed a new preliminary prospectus
KIRKLAND, QC, March 24, 2016 /CNW Telbec/ - Manitex Capital Inc. ("Manitex") announces that its' affiliate, Ortho Regenerative Technologies Inc. ("Ortho RTi"), has filed a new preliminary prospectus with the securities regulatory authorities of all provinces and territories in Canada. The new preliminary prospectus includes audited financial statements as at January 31, 2016.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
